Urologie最新文献_第10页

[Management of immune-related adverse events]. [免疫相关不良事件的管理]。

IF 0.5 4区医学

Urologie Pub Date : 2025-03-01 DOI: 10.1007/s00120-024-02517-x

Marika Henriette Princk, Mascha Pervan, Jörg Riedl

引用次数: 0

BvDU Kurz notiert. BvDU简短注释。

IF 0.5 4区医学

Urologie Pub Date : 2025-03-01 DOI: 10.1007/s00120-025-02545-1

引用次数: 0

[Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer]. [2025年的放射性核素治疗：治疗转移性去势抵抗性前列腺癌的核医学选择]。

IF 0.5 4区医学

Urologie Pub Date : 2025-03-01 Epub Date: 2025-02-21 DOI: 10.1007/s00120-025-02526-4

Luisa Willner, Robert Tauber, Matthias Eiber

引用次数: 0

[Role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging]. 前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描（PSMA-PET/CT）在分期中的作用。

IF 0.5 4区医学

Urologie Pub Date : 2025-03-01 Epub Date: 2025-01-22 DOI: 10.1007/s00120-024-02512-2

Claudia Kesch, Tobias Franiel, Christoph Berliner, Wolfgang P Fendler, Ken Herrmann, Boris Hadaschik

{"title":"[Role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging].","authors":"Claudia Kesch, Tobias Franiel, Christoph Berliner, Wolfgang P Fendler, Ken Herrmann, Boris Hadaschik","doi":"10.1007/s00120-024-02512-2","DOIUrl":"10.1007/s00120-024-02512-2","url":null,"abstract":"The superiority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) over conventional staging methods such as computed tomography (CT) and bone scintigraphy has now been demonstrated for almost all clinical stages of prostate cancer. In primary diagnostics, PSMA-PET/CT is therefore the new standard for risk-adapted whole-body staging. At the same time, PSMA-PET/CT provides a new risk-based classification for predicting overall survival across all early and late stages of the disease. However, the clinical implications of this information are not yet fully understood, particularly as data on systemic therapy for metastatic prostate cancer are still based on conventional imaging. For this reason, clinical follow-up is usually still carried out using conventional imaging. The Prostate Cancer Working Group 4 criteria will represent an initial consensus on therapy monitoring using PSMA-PET/CT. To monitor treatment response using PSMA PET/CT in metastatic castration resistant prostate cancer, there is already a framework (RECIP 1.0) in place. There is no doubt that PSMA PET/CT should be performed prior to PSMA radioligand therapy to optimize patient selection.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"220-228"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Treatment algorithm following first-line therapy failure in metastatic prostate cancer]. 【转移性前列腺癌一线治疗失败后的治疗方案】。

IF 0.5 4区医学

Urologie Pub Date : 2025-03-01 Epub Date: 2025-01-21 DOI: 10.1007/s00120-024-02505-1

Christian Thomas, Axel S Merseburger

{"title":"[Treatment algorithm following first-line therapy failure in metastatic prostate cancer].","authors":"Christian Thomas, Axel S Merseburger","doi":"10.1007/s00120-024-02505-1","DOIUrl":"10.1007/s00120-024-02505-1","url":null,"abstract":"This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy. Although significant progress has been made in the primary treatment of hormone-sensitive prostate cancer, the management of mCRPC remains a clinical challenge. The article outlines the diagnostic criteria for mCRPC, which can be confirmed through biochemical progression and imaging techniques. Various drug classes are available for the treatment of mCRPC after first-line therapy failure, including androgen receptor signaling pathway inhibitors (ARPI), chemotherapeutics such as docetaxel and cabazitaxel, as well as newer agents like poly(ADP-ribose) polymerase (PARP) inhibitors and prostate-specific membrane antigen (PSMA)-based radioligand therapies. These agents are used as monotherapy or in combination, depending on the patient's status and treatment history. Choosing the appropriate follow-up therapy after first-line failure is often difficult because current study results are mostly based on older treatment concepts. Precise, molecular-based treatment planning could play a key role here. Molecular markers such as BRCA 1/2 mutations and imaging techniques like PSMA-PET/CT can help identify the most suitable therapy for individual patients. For example, patients with BRCA 1/2 mutations may benefit from a combination of PARP and ARPI therapy, while those with high PSMA levels may be considered for PSMA radioligand therapy. Thus, therapeutic options for the treatment of mCRPC are now diverse and promising, with the challenge being to determine the right sequences and combinations based on the individual patient profile.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"229-236"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Smart assistants: service robots in action]. [智能助手：服务机器人的行动]。

IF 0.5 4区医学

Urologie Pub Date : 2025-02-27 DOI: 10.1007/s00120-025-02537-1

Domenic Sommer, Stefan Riedel, Sebastian Schmidt

引用次数: 0

[The key role of advanced practice nurses]. 【高级实习护士的关键作用】。

IF 0.5 4区医学

Urologie Pub Date : 2025-02-27 DOI: 10.1007/s00120-025-02541-5

Sandra Bensch

引用次数: 0

[Proof of effectiveness required: antimicrobial wound dressings]. [需要有效性证明：抗菌伤口敷料]。